BindingDB logo
myBDB logout

73 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27377864 55 Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors.EBI Broad Institute of MIT and Harvard
27186676 186 Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.EBI West China Hospital of Sichuan University
26890116 30 Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.EBI University of Milan
27060764 30 Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.EBI Sungkyunkwan University
26443078 108 Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.EBI Sichuan University
26689485 18 Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.EBI Orchid Chemicals& Pharmaceuticals Ltd
26753813 22 Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.EBI University of Minnesota
26331334 99 Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.EBI Guangzhou Institute of Biomedicine and Health
26086931 38 Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.EBI Shandong University
26264503 46 Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.EBI University of Minnesota
26287310 87 Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.EBI University College London
25637120 94 Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).EBI St Jude Children's Research Hospital
25905694 24 Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.EBI Istituto Ortopedico Rizzoli (IOR)
25454270 82 Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.EBI TBA
25238284 52 Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.EBI Roche Pharmaceutical Research and Early Development
25218912 103 Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.EBI Chinese Academy of Sciences
24766560 16 Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.EBI Taipei Medical University
24588105 56 Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.EBI Universit£ degli Studi di Siena
24565573 35 4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.EBI Universit£ degli Studi di Ferrara
24742384 90 Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.EBI Universit£ di Milano
23368884 80 Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.EBI Broad Institute of MIT and Harvard
23252603 35 Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.EBI Heinrich Heine Universit£t
23061376 63 Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.EBI Roche R&D Center-China Ltd.
23009203 39 Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.EBI University of Illinois at Chicago
22642300 160 Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.EBI Kyoto Prefectural University of Medicine
21874153 54 Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.EBI Broad Institute of Harvard and MIT
18809328 64 Optimization of a series of potent and selective ketone histone deacetylase inhibitors.EBI IRBM/Merck Research Laboratories
18182289 127 Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).EBI Merck Research Laboratories
18247554 134 Histone deacetylase inhibitors: from bench to clinic.EBI Menarini Ricerche
16987657 45 A series of novel, potent, and selective histone deacetylase inhibitors.EBI IRBM/Merck Research Laboratories
15109626 20 Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.EBI Institute of Technology
21548582 57 Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.EBI University of Illinois at Chicago
21634430 218 Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.EBI S*BIO Pte Ltd.
21696956 243 A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.EBI Broad Institute of Harvard and MIT
21080647 27 Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.EBI Chroma Therapeutics Ltd.
21417297 220 Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.EBI Universita` degli Studi di Siena
19966789 40 Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.EBI The Scripps Research Institute
20451378 107 Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.EBI S *BIO Pte Ltd
20381359 17 Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222.EBI Universit£ degli Studi di Salerno
20143778 70 Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.EBI Curis Inc
19906529 22 Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.EBI Ortho-Biotech Oncology Research& Development
19699639 58 Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.EBI MethylGene Inc.
19359173 51 Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.EBI Sigma-Tau Research and Development
19441846 35 Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.EBI IRBM/Merck Research Laboratories
19285395 66 N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.EBI R&D Sigma-Tau SpA
19268585 30 Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).EBI Merck Research Laboratories
19181524 46 N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.EBI S *BIO Pte Ltd
19114304 44 SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).EBI MethylGene Inc.
18951790 109 SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).EBI Merck Research Laboratories
18672316 41 Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.EBI Institute of Organic Synthesis
18060775 67 Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).EBI Merck Research Laboratories
24114842 25 The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.BDB Soochow University
23897821 60 Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.BDB Genentech, Inc.
27977115 24 LSD1 Substrate Binding and Gene Expression Are Affected by HDAC1-Mediated Deacetylation.BDB Wayne State University
27454931 24 Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.BDB Friedrich Miescher Institute for Biomedical Research
27064299 8 Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile.BDB Broad Institute
26640968 60 An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in -Cell Protection.BDB Broad Institute of Harvard and MIT
25699604 74 Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.BDB University of Florida College of Medicine; Northwest Agriculture and Forestry University
20139990 8 Chemical phylogenetics of histone deacetylases.BDB Dana-Farber Cancer Institute
18370373 48 A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.BDB IRBM/Merck
18570366 9 Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.BDB MethylGene Inc.